MedTrace Logo

BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

NCT04932863 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-08-08

No results posted yet for this study

Summary

In this Italian observational study the antibody titer reactogenicity to Pfizer Severe Acute Respiratory Syndrome (SARS) - Coronavirus (CoV-2) RNA vaccine in cancer patients under active antitumor treatment will be evaluated at 21 and 42 days and after 6 months. Furthermore patients safety will be monitored. Factors affecting immunogenicity (or lack of), including cancer treatment, will be the primary aim of the study.

Conditions

  • Neoplasms
  • Cancer, Treatment-Related

Interventions

BIOLOGICAL

BNT162b2 mRNA Covid-19 Vaccine

Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.

Sponsors & Collaborators

  • Universita degli Studi di Genova

    collaborator OTHER

  • Ente Ospedaliero Ospedali Galliera

    lead OTHER

Principal Investigators

  • Andrea De Censi, MD · E.O. Ospedali Galliera

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2022-03-15
Completion
2023-03-15

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04932863 on ClinicalTrials.gov